SQUARE today symbolizes a name a state of mind.

. But its journey to the growth and prosperity has been no bed of roses. From the inception in 1958, it has today bu rgeoned into one of the top line conglomerates in Bangladesh. Square Pharmaceuti cals Ltd., the flagship company, is holding the strong leadership position in th e pharmaceutical industry of Bangladesh since 1985 and is now on its way to beco ming a high performance global player. SQUARE Pharmaceuticals Limited is the lar gest pharmaceutical company in Bangladesh and it has been continuously in the 1s t position among all national and multinational companies since 1985. It was est ablished in 1958 and converted into a public limited company in 1991. The sales turnover of SPL was more than Taka 11.46 Billion (US$ 163.71 million) with about 16.43% market share (April 2009 March 2010) having a growth rate of about 16.72%.

Square Hospitals Limited, a concern of Square Group is a 320-bed tertiary care h ospital. The hospital is an affiliate partner of Methodist Healthcare, Memphis, Tennessee, USA, SingHealth, Singapore, Bangkok Hospital Medical Centre, Thailand and Christian Medical College, Vellore, India. A lot of physicians have joined from CMC-Vellore, India. Bangladeshi Physicians with impeccable reputation are also part of the medical team. Huge emphasis has been made on quality nursing services, as we have trained over a hundred nurses for over a year. We have nurse educators from Australia, UK, India and the Phili ppines. Nurses and technicians have already received training from CMC-Vellore w hich continues to be an on- going process. Square Hospital is located in the heart of Dhaka and aims to serve greater porti on of the capital city. At present it comprises of two buildings on either side of Panthapath connected by an over-bridge. The main hospital building is 18 stor ies and is approximately 450,000 sq.ft. The second building (ASTRAS) is located across the street and is 16 stories with 136,000 sq.ft. The second building is e xpected to be operational by 2011. Both facilities are constructed in accordance with US Fire and Building safety standards The outpatient department of this hospital can serve up to 1200 patients daily, through 60 examination rooms. To ensure optimum healthcare-hospitality, the pati ents are closely monitored in their waiting times in outpatient clinics, emergen cy and admissions.

Ace Paracetamol Ace Plus Paracetamol & Caffeine Ace XR Paracetamol Acetram Paracetamol+Tramadol Adovas Adhatoda vasica Adryl

Diphenhydramine HCl Afun Clotrimazole Afun VT Clotrimazole Alacot Eye Drops Olopatadine HCl Alarid Ketotifen Fumarate Alatrol Cetirizine HCl Almex Albendazole Ambrox Ambroxol AmCivit Amlaki rashayan Amlosart Amlodipine+Olmesartan Medoxomil Amodis Metronidazole Amodis IV Infusion Metronidazole Anadol Tramadol HCl Anclog Clopidogrel Anclog Plus Clopidogrel + Aspirin Anespine Bupivacaine HCl+Dextrose Angilock Losartan potassium + Hydrochlorthiazide Angilock plus Losartan potassium + Hydrochlorthiazide Angivent MR Trimetazidine HCl Anleptic Carbamazepine Anoxa 10

Oxazepam Anril 0.5 Nitroglycerin Anril Injection Nitroglycerin Anril spray Nitroglycerin Anril SR Nitroglycerin Ansulin Insulin Human (rDNA) AnsuPen Reusable Insulin Pen Antazol Xylometazoline HCl Antazol Plus Sodium Cromoglicate + Xylometazoline HCl Antista Chlorpheniramine Maleate Antiva Adefovir Dipivoxil Anzitor Atorvastatin Apsol Amlexanox Arubin Herbal hematinic Atreon Aztreonam Aviflu Oseltamivir phosphate 1958 : Debut of SQUARE Pharma as a Partnership Firm. 1964 : Converted into a Private Limited Company. 1974 : Technical Collaboration with Janssen Pharmaceuticals, Belgium, a subsidia ry of Johnson and Johnson International, USA. 1982 : Licensing Agreement signed with F. Hoffman-La Roche & Co Ltd., Switzerlan d. 1985 : Achieved market-leadership in the pharmaceutical market of Bangladesh amo ng all national and multinational companies. 1987 : Pioneer in pharmaceutical export from Bangladesh. 1991 : Converted into a Public Limited Company 1994 : Initial Public Offering of shares of SQUARE Pharmaceuticals Ltd. 1995 : Chemical Division of SQUARE Pharmaceuticals Ltd. starts production of Act ive Pharmaceutical Ingredients (API). 1997 : Won the National Export trophy for exporting pharmaceuticals.

1998 : Agro-chemicals & Veterinary Products division of SQUARE Pharmaceuticals s tarts its operation. 2001 : US FDA/UK MCA standard new pharmaceutical factory goes into operation bui lt under the supervision of Bovis Lend Lease, UK. 2004 : SQUARE enlisted as UNICEF's global supplier. 2005 : New State-of-the-Art SQUARE Cephalosporins Ltd. goes into operation; buil t under the supervision of TELSTAR S.A. of Spain as per US FDA/ UK MHRA requirem ents. 2007 : SQUARE Pharmaceuticals Ltd., Dhaka Unit gets the UK MHRA approval. 2009 : Starts manufacturing of insulin maintaining quality standards of US FDA & UK MHRA. Dedicated hormone & steroid products manufacturing facility complying with the current Good Manufacturing Practice (cGMP) of WHO, US FDA & UK MHRA sta rts operation. 2012 : SQUARE Pharmaceuticals Ltd., Dhaka Unit and SQUARE Cephalosporins Ltd. ge t the Therapeutic Goods Administration(TGA) of Australia approval Our Mission is to produce and provide quality & innovative healthcare relief for people, maintain stringently ethical standard in business operation also ensuri ng benefit to the shareholders, stakeholders and the society at large. Vision We view business as a means to the material and social wellbeing of the investor s, employees and the society at large, leading to accretion of wealth through fi nancial and moral gains as a part of the process of the human civilization. Objective Our objectives are to conduct transparent business operation based on market mec hanism within the legal & social framework with aims to attain the mission refle cted by our vision.

SQUARE has invested in state of the art formulation plants aligned to regulated market standards. Six manufacturing units of the Dhaka site can produce pharmace utical products maintaining cGMP requirement for highly regulated markets in Eur ope, Australia and USA. Other five manufacturing units at Pabna site are produci ng finished formulations targeting markets in ASEAN, SAARC and marketing in RoW region. We have 700 product approvals for export markets and 900 product approva ls for Bangladesh market. Present Markets